Compugen

CGEN

Biotechnology · Healthcare

Price

$2.62

-0.04 (-1.32%)

Market Cap

$247.3M

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Good

Valuation

Good

Track this stock — start free trial

Share count rising — dilution

+11.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 84.2M (2021) → 93.8M (2025)

Winston Score History

The full picture

Compugen is an Israeli biotechnology company that uses computers and algorithms to discover new drug targets — mainly for cancer treatments. Instead of running traditional lab experiments first, it uses its own software to predict which proteins in the human body could be targeted by new medicines. Its main customers are large pharmaceutical companies that license Compugen's discoveries to develop their own drugs.

Compugen makes money primarily through research collaborations and licensing deals with big pharma partners, rather than selling drugs directly to patients. It operates mainly out of Israel with a presence in the United States, and its competitive edge comes from its proprietary computational platform, which is difficult for rivals to replicate quickly. The key risk is that the company depends heavily on a small number of partnership deals, so losing or failing to renew a major collaboration could significantly hurt its revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+107.0% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

+10.8% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$23M/ year

↓ Declining (-8% vs prior year)

31.3% of revenue

1.7x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

2.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$125M cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

Compugen is growing revenue at 107% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-3.5%

Thin — -3.5% gross margin

Profit after running costs

Operating Margin

-339.6%

Losing money on operations — -339.6%

Return on the money invested

ROCE

34.1%

Exceptional — 34.1% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+234.2%

Fast-growing sales (+234.2% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

Weak — only 0% of profit becomes cash

Spare cash per sale

FCF Margin

0.0%

Thin free cash flow (0.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

100.00x

—

Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

7.0x

Attractive valuation — P/E 7.0

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial